Putative EPHX1 enzyme activity is related with risk of lung and upper aerodigestive tract cancers: A comprehensive meta-analysis

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Li, Xiang ^a   Hu, Zheng ^b   Qu, Xinshun ^c   Zhu, Jiadong ^a   Li, Lin ^a   Ring, Brian Z ^d   Su, Li ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Chinese Academy of Sciences and China National Center for Bioinformation   (China)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

^d Yigene Inc   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EPOXIDE HYDROLASE 1; HYDROLASE; UNCLASSIFIED DRUG; EPHX1 PROTEIN, HUMAN; EPOXIDE HYDROLASE;

ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER RISK; CARCINOGENESIS; CIGARETTE SMOKING; COLON ADENOMA; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; ENZYME ACTIVITY; ESOPHAGUS CANCER; ETHNICITY; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; LARYNX CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); OROPHARYNX CANCER; RECTUM ADENOMA; RESPIRATORY TRACT CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; ALLELE; CASE CONTROL STUDY; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; HEAD AND NECK TUMOR; LUNG TUMOR; META ANALYSIS; METABOLISM; RISK FACTOR; SMOKING;

NICOTIANA TABACUM;

ALLELES; CASE-CONTROL STUDIES; EPOXIDE HYDROLASES; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; POLYMORPHISM, GENETIC; RISK FACTORS; SMOKING;

EID: 79952801772     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014749     Document Type: Article

References (110)

1. Oesch F, (1973) Mammalian epoxide hydrases: inducible enzymes catalysing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds. Xenobiotica 3: 305-340.
2. Morisseau C, Hammock BD, (2005) Epoxide hydrolases: mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol 45: 311-333.
3. Decker M, Arand M, Cronin A, (2009) Mammalian epoxide hydrolases in xenobiotic metabolism and signalling. Arch Toxicol 83: 297-318.
4. Sims P, Grover PL, Swaisland A, Pal K, Hewer A, (1974) Metabolic activation of benzo-(a)pyrene proceeds by a diol-epoxide. Nature 252: 326-328.
5. Seidegard J, DePierre JW, (1983) Microsomal epoxide hydrolase. Properties, regulation and function. Biochim Biophys Acta 695: 251-270.
6. Fretland AJ, Omiecinski CJ, (2000) Epoxide hydrolases: biochemistry and molecular biology. Chem Biol Interact 129: 41-59.
7. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ, (1994) Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet 3: 421-428.
8. Hassett C, Lin J, Carty CL, Laurenzana EM, Omiecinski CJ, (1997) Human hepatic microsomal epoxide hydrolase: comparative analysis of polymorphic expression. Arch Biochem Biophys 337: 275-283.
9. Benhamou S, Reinikainen M, Bouchardy C, Dayer P, Hirvonen A, (1998) Association between lung cancer and microsomal epoxide hydrolase genotypes. Cancer Res 58: 5291-5293.
10. Gsur A, Zidek T, Schnattinger K, Feik E, Haidinger G, et al. (2003) Association of microsomal epoxide hydrolase polymorphisms and lung cancer risk. Br J Cancer 89: 702-706.
11. Park JY, Chen L, Elahi A, Lazarus P, Tockman MS, (2005) Genetic analysis of microsomal epoxide hydrolase gene and its association with lung cancer risk. Eur J Cancer Prev 14: 223-230.
12. Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, et al. (2008) A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogenesis 29: 1164-1169.
13. Jourenkova-Mironova N, Mitrunen K, Bouchardy C, Dayer P, Benhamou S, et al. (2000) High-activity microsomal epoxide hydrolase genotypes and the risk of oral, pharynx, and larynx cancers. Cancer Res 60: 534-536.
14. Park JY, Schantz SP, Lazarus P, (2003) Epoxide hydrolase genotype and orolaryngeal cancer risk: interaction with GSTM1 genotype. Oral Oncol 39: 483-490.
15. Sachse C, Smith G, Wilkie MJ, Barrett JH, Waxman R, et al. (2002) A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer. Carcinogenesis 23: 1839-1849.
16. Huang WY, Chatterjee N, Chanock S, Dean M, Yeager M, et al. (2005) Microsomal epoxide hydrolase polymorphisms and risk for advanced colorectal adenoma. Cancer Epidemiol Biomarkers Prev 14: 152-157.
17. Srivastava DS, Mandhani A, Mittal RD, (2008) Genetic polymorphisms of cytochrome P450 CYP1A1 (*2A) and microsomal epoxide hydrolase gene, interactions with tobacco-users, and susceptibility to bladder cancer: a study from North India. Arch Toxicol 82: 633-639.
18. Spurdle AB, Chang JH, Byrnes GB, Chen X, Dite GS, et al. (2007) A systematic approach to analysing gene-gene interactions: polymorphisms at the microsomal epoxide hydrolase EPHX and glutathione S-transferase GSTM1, GSTT1, and GSTP1 loci and breast cancer risk. Cancer Epidemiol Biomarkers Prev 16: 769-774.
19. Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y, (2006) EPHX1 polymorphisms and the risk of lung cancer: a HuGE review. Epidemiology 17: 89-99.
20. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin. Trials 7: 177-188.
21. Petiti DB, (1994) Meta-analysis Decision Analysis and Cost-Effectiveness Analysis, Vol.24. Oxford University Press.
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG, (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
23. Patsopoulos NA, Evangelou E, Ioannidis JP, (2008) Sensitivity of between-study heterogeneity in meta-analysis: proposed metrics and empirical evaluation. Int J Epidemiol 37: 1148-1157.
24. Begg CB, Mazumdar M, (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
25. Egger M, Davey Smith G, Schneider M, Minder C, (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
26. Zhou W, Thurston SW, Liu G, Xu LL, Miller DP, et al. (2001) The interaction between microsomal epoxide hydrolase polymorphisms and cumulative cigarette smoking in different histological subtypes of lung cancer. Cancer Epidemiol Biomarkers Prev 10: 461-466.
27. de Assis S, Ambrosone CB, Wustrack S, Krishnan S, Freudenheim JL, et al. (2002) Microsomal epoxide hydrolase variants are not associated with risk of breast cancer. Cancer Epidemiol Biomarkers Prev 11: 1697-1698.
28. Tsai YY, McGlynn KA, Hu Y, Cassidy AB, Arnold J, et al. (2003) Genetic susceptibility and dietary patterns in lung cancer. Lung Cancer 41: 269-281.
29. Gemignani F, Landi S, Szeszenia-Dabrowska N, Zaridze D, Lissowska J, et al. (2007) Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes. Carcinogenesis 28: 1287-1293.
30. Rosenberger A, Illig T, Korb K, Klopp N, Zietemann V, et al. (2008) Do genetic factors protect for early onset lung cancer? A case control study before the age of 50 years. BMC Cancer 8: 60.
31. Kiran M, Chawla YK, Jain M, Kaur J, (2009) Haplotypes of microsomal epoxide hydrolase and x-ray cross-complementing group 1 genes in Indian hepatocellular carcinoma patients. DNA Cell Biol 28: 573-577.
32. Smith CA, Harrison DJ, (1997) Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 350: 630-633.
33. Persson I, Johansson I, Lou YC, Yue QY, Duan LS, et al. (1999) Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients. Int J Cancer 81: 325-329.
34. London SJ, Smart J, Daly AK, (2000) Lung cancer risk in relation to genetic polymorphisms of microsomal epoxide hydrolase among African-Americans and Caucasians in Los Angeles County. Lung Cancer 28: 147-155.
35. Yoshikawa M, Hiyama K, Ishioka S, Maeda H, Maeda A, et al. (2000) Microsomal epoxide hydrolase genotypes and chronic obstructive pulmonary disease in Japanese. Int J Mol Med 5: 49-53.
36. To-Figueras J, Gene M, Gomez-Catalan J, Pique E, Borrego N, et al. (2001) Lung cancer susceptibility in relation to combined polymorphisms of microsomal epoxide hydrolase and glutathione S-transferase P1. Cancer Lett 173: 155-162.
37. Wu X, Gwyn K, Amos CI, Makan N, Hong WK, et al. (2001) The association of microsomal epoxide hydrolase polymorphisms and lung cancer risk in African-Americans and Mexican-Americans. Carcinogenesis 22: 923-928.
38. Yin L, Pu Y, Liu TY, Tung YH, Chen KW, et al. (2001) Genetic polymorphisms of NAD(P)H quinone oxidoreductase, CYP1A1 and microsomal epoxide hydrolase and lung cancer risk in Nanjing, China. Lung Cancer 33: 133-141.
39. Zhao H, Spitz MR, Gwyn KM, Wu X, (2002) Microsomal epoxide hydrolase polymorphisms and lung cancer risk in non-Hispanic whites. Mol Carcinog 33: 99-104.
40. Cajas-Salazar N, Au WW, Zwischenberger JB, Sierra-Torres CH, Salama SA, et al. (2003) Effect of epoxide hydrolase polymorphisms on chromosome aberrations and risk for lung cancer. Cancer Genet Cytogenet 145: 97-102.
41. Voho A, Metsola K, Anttila S, Impivaara O, Jarvisalo J, et al. (2006) EPHX1 gene polymorphisms and individual susceptibility to lung cancer. Cancer Lett 237 (1): 102-108.
42. McKay JD, Hashibe M, Hung RJ, Wakefield J, Gaborieau V, et al. (2008) Sequence variants of NAT1 and NAT2 and other xenometabolic genes and risk of lung and aerodigestive tract cancers in Central Europe. Cancer Epidemiol Biomarkers Prev 17: 141-147.
43. Rotunno M, Yu K, Lubin JH, Consonni D, Pesatori AC, et al. (2009) Phase I metabolic genes and risk of lung cancer: multiple polymorphisms and mRNA expression. PLoS One 4: e5652.
44. Graziano C, Comin CE, Crisci C, Novelli L, Politi L, et al. (2009) Functional polymorphisms of the microsomal epoxide hydrolase gene: a reappraisal on an early-onset lung cancer patients series. Lung Cancer 63: 187-193.
45. Timofeeva M, Kropp S, Sauter W, Beckmann L, Rosenberger A, et al. (2010) Genetic polymorphisms of MPO, GSTT1, GSTM1, GSTP1, EPHX1 and NQO1 as risk factors of early-onset lung cancer. Int J Cancer 127: 1547-61.
46. Amador AG, Righi PD, Radpour S, Everett ET, Weisberger E, et al. (2002) Polymorphisms of xenobiotic metabolizing genes in oropharyngeal carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93: 440-445.
47. To-Figueras J, Gene M, Gomez-Catalan J, Pique E, Borrego N, et al. (2002) Microsomal epoxide hydrolase and glutathione S-transferase polymorphisms in relation to laryngeal carcinoma risk. Cancer Lett 187: 95-101.
48. Casson AG, Zheng Z, Chiasson D, MacDonald K, Riddell DC, et al. (2003) Associations between genetic polymorphisms of Phase I and II metabolizing enzymes, p53 and susceptibility to esophageal adenocarcinoma. Cancer Detect Prev 27: 139-146.
49. Wenghoefer M, Pesch B, Harth V, Broede P, Fronhoffs S, et al. (2003) Association between head and neck cancer and microsomal epoxide hydrolase genotypes. Arch Toxicol 77: 37-41.
50. Zhang JH, Jin X, Li Y, Wang R, Guo W, et al. (2003) Epoxide hydrolase Tyr113His polymorphism is not associated with susceptibility to esophageal squamous cell carcinoma in population of North China. World J Gastroenterol 9: 2654-2657.
51. Casson AG, Zheng Z, Porter GA, Guernsey DL, (2006) Genetic polymorphisms of microsomal epoxide hydroxylase and glutathione S-transferases M1, T1 and P1, interactions with smoking, and risk for esophageal (Barrett) adenocarcinoma. Cancer Detect Prev 30: 423-431.
52. Lin YC, Wu DC, Lee JM, Hsu HK, Kao EL, et al. (2006) The association between microsomal epoxide hydrolase genotypes and esophageal squamous-cell-carcinoma in Taiwan: interaction between areca chewing and smoking. Cancer Lett 237: 281-288.
53. Boccia S, Cadoni G, Sayed-Tabatabaei FA, Volante M, Arzani D, et al. (2008) CYP1A1, CYP2E1, GSTM1, GSTT1, EPHX1 exons 3 and 4, and NAT2 polymorphisms, smoking, consumption of alcohol and fruit and vegetables and risk of head and neck cancer. J Cancer Res Clin Oncol 134: 93-100.
54. Lacko M, Roelofs HM, Te Morsche RH, Voogd AC, Oude Ophuis MB, et al. (2008) Microsomal epoxide hydrolase genotypes and the risk for head and neck cancer. Head Neck 30: 836-844.
55. Varela-Lema L, Ruano-Ravina A, Juiz Crespo MA, Kelsey KT, Loidi L, et al. (2008) CYP1A1, mEH, and GSTM1 Polymophisms and Risk of Oral and Pharyngeal Cancer: A Spanish Case-Control Study. J Oncol 2008: 741310.
56. Ihsan R, Chattopadhyay I, Phukan R, Mishra AK, Purkayastha J, et al. (2010) Role of epoxide hydrolase 1 gene polymorphisms in esophageal cancer in a high-risk area in India. J Gastroenterol Hepatol 25: 1456-1462.
57. Soucek P, Susova S, Mohelnikova-Duchonova B, Gromadzinska J, Moraviec-Sztandera A, et al. (2010) Neoplasma 57: 415-421.
58. Harrison DJ, Hubbard AL, MacMillan J, Wyllie AH, Smith CA, (1999) Microsomal epoxide hydrolase gene polymorphism and susceptibility to colon cancer. Br J Cancer 79: 168-171.
59. Landi S, Gemignani F, Moreno V, Gioia-Patricola L, Chabrier A, et al. (2005) A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of colorectal cancer. Pharmacogenet Genomics 15: 535-546.
60. Robien K, Curtin K, Ulrich CM, Bigler J, Samowitz W, et al. (2005) Microsomal epoxide hydrolase polymorphisms are not associated with colon cancer risk. Cancer Epidemiol Biomarkers Prev 14: 1350-1352.
61. Tranah GJ, Chan AT, Giovannucci E, Ma J, Fuchs C, et al. (2005) Epoxide hydrolase and CYP2C9 polymorphisms, cigarette smoking, and risk of colorectal carcinoma in the Nurses' Health Study and the Physicians' Health Study. Mol Carcinog 44: 21-30.
62. van der Logt EM, Bergevoet SM, Roelofs HM, Te Morsche RH, Dijk Y, et al. (2006) Role of epoxide hydrolase, NAD(P)H:quinone oxidoreductase, cytochrome P450 2E1 or alcohol dehydrogenase genotypes in susceptibility to colorectal cancer. Mutat Res 593: 39-49.
63. Kiss I, Orsos Z, Gombos K, Bogner B, Csejtei A, et al. (2007) Association between allelic polymorphisms of metabolizing enzymes (CYP 1A1, CYP 1A2, CYP 2E1, mEH) and occurrence of colorectal cancer in Hungary. Anticancer Res 27: 2931-2937.
64. Skjelbred CF, Saebo M, Hjartaker A, Grotmol T, Hansteen IL, et al. (2007) Meat, vegetables and genetic polymorphisms and the risk of colorectal carcinomas and adenomas. BMC Cancer 7: 228.
65. Cotterchio M, Boucher BA, Manno M, Gallinger S, Okey AB, et al. (2008) Red meat intake, doneness, polymorphisms in genes that encode carcinogen-metabolizing enzymes, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 17: 3098-3107.
66. Cleary SP, Cotterchio M, Shi E, Gallinger S, Harper P, (2010) Cigarette smoking, genetic variants in carcinogen-metabolizing enzymes, and colorectal cancer risk. Am J Epidemiol 172: 1000-1014.
67. Hlavata I, Vrana D, Smerhovsky Z, Pardini B, Naccarati A, et al. (2010) Association between exposure-relevant polymorphisms in CYP1B1, EPHX1, NQO1, GSTM1, GSTP1 and GSTT1 and risk of colorectal cancer in a Czech population. Oncol Rep 24: 1347-1353.
68. Cortessis V, Siegmund K, Chen Q, Zhou N, Diep A, et al. (2001) A case-control study of microsomal epoxide hydrolase, smoking, meat consumption, glutathione S-transferase M3, and risk of colorectal adenomas. Cancer Res 61: 2381-2385.
69. Ulrich CM, Bigler J, Whitton JA, Bostick R, Fosdick L, et al. (2001) Epoxide hydrolase Tyr113His polymorphism is associated with elevated risk of colorectal polyps in the presence of smoking and high meat intake. Cancer Epidemiol Biomarkers Prev 10: 875-882.
70. Tiemersma EW, Bunschoten A, Kok FJ, Glatt H, de Boer SY, et al. (2004) Effect of SULT1A1 and NAT2 genetic polymorphism on the association between cigarette smoking and colorectal adenomas. Int J Cancer 108: 97-103.
71. Tranah GJ, Giovannucci E, Ma J, Fuchs C, Hankinson SE, et al. (2004) Epoxide hydrolase polymorphisms, cigarette smoking and risk of colorectal adenoma in the Nurses' Health Study and the Health Professionals Follow-up Study. Carcinogenesis 25: 1211-1218.
72. Mitrou PN, Watson MA, Loktionov AS, Cardwell C, Gunter MJ, et al. (2007) Role of NQO1C609T and EPHX1 gene polymorphisms in the association of smoking and alcohol with sporadic distal colorectal adenomas: results from the UKFSS Study. Carcinogenesis 28: 875-882.
73. Northwood EL, Elliott F, Forman D, Barrett JH, Wilkie MJ, et al. (2010) Polymorphisms in xenobiotic metabolizing enzymes and diet influence colorectal adenoma risk. Pharmacogenet Genomics 20: 315-326.
74. Sarmanova J, Susova S, Gut I, Mrhalova M, Kodet R, Adamek J, et al. (2004) Breast cancer: role of polymorphisms in biotransformation enzymes. Eur J Hum Genet 12: 848-854.
75. Justenhoven C, Hamann U, Schubert F, Zapatka M, Pierl CB, et al. (2008) Breast cancer: a candidate gene approach across the estrogen metabolic pathway. Breast Cancer Res Treat 108: 137-149.
76. Khedhaier A, Hassen E, Bouaouina N, Gabbouj S, Ahmed SB, et al. (2008) Implication of Xenobiotic Metabolizing Enzyme gene (CYP2E1, CYP2C19, CYP2D6, mEH and NAT2) polymorphisms in breast carcinoma. BMC Cancer 8: 109.
77. Sangrajrang S, Sato Y, Sakamoto H, Ohnami S, Laird NM, et al. (2009) Genetic polymorphisms of estrogen metabolizing enzyme and breast cancer risk in Thai women. Int J Cancer 125: 837-843.
78. The MARIE-GENICA Consortium (2010) Postmenopausal estrogen monotherapy-associated breast cancer risk is modified by CYP17A1_-34_T&C polymorphism. Breast Cancer Res Treat 120: 737-744.
79. Brockmoller J, Kaiser R, Kerb R, Cascorbi I, Jaeger V, et al. (1996) Polymorphic enzymes of xenobiotic metabolism as modulators of acquired P53 mutations in bladder cancer. Pharmacogenetics 6: 535-545.
80. Broberg K, Bjork J, Paulsson K, Hoglund M, Albin M, (2005) Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis 26: 1263-1271.
81. Figueroa JD, Malats N, Garcia-Closas M, Real FX, Silverman D, et al. (2008) Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis 29: 1955-1962.
82. Hsu LI, Chiu AW, Huan SK, Chen CL, Wang YH, et al. (2008) SNPs of GSTM1, T1, P1, epoxide hydrolase and DNA repair enzyme XRCC1 and risk of urinary transitional cell carcinoma in southwestern Taiwan. Toxicol Appl Pharmacol 228: 144-155.
83. Sarmanova J, Benesova K, Gut I, Nedelcheva-Kristensen V, Tynkova L, et al. (2001) Genetic polymorphisms of biotransformation enzymes in patients with Hodgkin's and non-Hodgkin's lymphomas. Hum Mol Genet 10: 1265-1273.
84. Lebailly P, Willett EV, Moorman AV, Roman E, Cartwright R, et al. (2002) Genetic polymorphisms in microsomal epoxide hydrolase and susceptibility to adult acute myeloid leukaemia with defined cytogenetic abnormalities. Br J Haematol 116: 587-594.
85. Clavel J, Bellec S, Rebouissou S, Menegaux F, Feunteun J, et al. (2005) Childhood leukaemia, polymorphisms of metabolism enzyme genes, and interactions with maternal tobacco, coffee and alcohol consumption during pregnancy. Eur J Cancer Prev 14: 531-540.
86. De Roos AJ, Gold LS, Wang S, Hartge P, Cerhan JR, et al. (2006) Metabolic gene variants and risk of non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 15: 1647-1653.
87. Lincz LF, Scorgie FE, Robertson R, Enno A, (2007) Genetic variations in benzene metabolism and susceptibility to multiple myeloma. Leuk Res 31: 759-763.
88. Gold LS, De Roos AJ, Brown EE, Lan Q, Milliken K, et al. (2009) Associations of common variants in genes involved in metabolism and response to exogenous chemicals with risk of multiple myeloma. Cancer Epidemiol 33: 276-280.
89. Silveira Vda S, Canalle R, Scrideli CA, Queiroz RG, Tone LG, (2010) Role of the CYP2D6, EPHX1, MPO, and NQO1 genes in the susceptibility to acute lymphoblastic leukemia in Brazilian children. Environ Mol Mutagen 51: 48-56.
90. Chauhan PS, Ihsan R, Yadav DS, Mishra AK, Bhushan B, et al. (2010) Association of Glutathione S-Transferase, EPHX, and p53 codon 72 Gene Polymorphisms with Adult Acute Myeloid Leukemia. DNA Cell Biol. 2010 Aug 23. [Epub ahead of print].
91. Wong NA, Rae F, Bathgate A, Smith CA, Harrison DJ, (2000) Polymorphisms of the gene for microsomal epoxide hydrolase and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a Caucasian population. Toxicol Lett 115: 17-22.
92. Tiemersma EW, Omer RE, Bunschoten A, van't Veer P, Kok FJ, et al. (2001) Role of genetic polymorphism of glutathione-S-transferase T1 and microsomal epoxide hydrolase in aflatoxin-associated hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 10: 785-791.
93. Kirk GD, Turner PC, Gong Y, Lesi OA, Mendy M, et al. (2005) Hepatocellular carcinoma and polymorphisms in carcinogen-metabolizing and DNA repair enzymes in a population with aflatoxin exposure and hepatitis B virus endemicity. Cancer Epidemiol Biomarkers Prev 14: 373-379.
94. Kiran M, Chawla YK, Kaur J, (2008) Glutathione-S-transferase and microsomal epoxide hydrolase polymorphism and viral-related hepatocellular carcinoma risk in India. DNA Cell Biol 27: 687-694.
95. De Roos AJ, Rothman N, Brown M, Bell DA, Pittman GS, et al. (2006) Variation in genes relevant to aromatic hydrocarbon metabolism and the risk of adult brain tumors. Neuro Oncol 8: 145-155.
96. Sierra-Torres CH, Au WW, Arrastia CD, Cajas-Salazar N, Robazetti SC, et al. (2003) Polymorphisms for chemical metabolizing genes and risk for cervical neoplasia. Environ Mol Mutagen 41: 69-76.
97. Nishino K, Sekine M, Kodama S, Sudo N, Aoki Y, et al. (2008) Cigarette smoking and glutathione S-transferase M1 polymorphism associated with risk for uterine cervical cancer. J Obstet Gynaecol Res 34: 994-1001.
98. Agudo A, Sala N, Pera G, Capella G, Berenguer A, et al. (2006) Polymorphisms in metabolic genes related to tobacco smoke and the risk of gastric cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 15: 2427-2434.
99. Boccia S, Sayed-Tabatabaei FA, Persiani R, Gianfagna F, Rausei S, et al. (2007) Polymorphisms in metabolic genes, their combination and interaction with tobacco smoke and alcohol consumption and risk of gastric cancer: a case-control study in an Italian population. BMC Cancer 7: 206.
100. Spurdle AB, Purdie DM, Webb PM, Chen X, Green A, et al. (2001) The microsomal epoxide hydrolase Tyr113His polymorphism: association with risk of ovarian cancer. Mol Carcinog 30: 71-78.
101. Baxter SW, Choong DY, Campbell IG, (2002) Microsomal epoxide hydrolase polymorphism and susceptibility to ovarian cancer. Cancer Lett 177: 75-81.
102. Ockenga J, Strunck S, Post C, Schulz HU, Halangk J, et al. (2009) The role of epoxide hydrolase Y113H gene variant in pancreatic diseases. Pancreas 38: e97-e101.
103. Mittal RD, Srivastava DL, (2007) Cytochrome P4501A1 and microsomal epoxide hydrolase gene polymorphisms: gene-environment interaction and risk of prostate cancer. DNA Cell Biol 26: 791-798.
104. IARC (2004) Tobacco smoking and involuntary smoking. Lyon International Agency for Research on Cancer.
105. Hecht SS, (2003) Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 3: 733-744.
106. Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J, (2005) The choice of a genetic model in the meta-analysis of molecular association studies. Int J Epidemiol 34: 1319-1328.
107. Minelli C, Thompson JR, Abrams KR, Lambert PC, (2005) Bayesian implementation of a genetic model-free approach to the meta-analysis of genetic association studies. Stat Med 24: 3845-3861.
108. Taioli E, (2008) Gene-environment interaction in tobacco-related cancers. Carcinogenesis 29: 1467-1474.
109. Higgins JP, Thompson SG, (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21: 1539-1958.
110. Higgins JP, (2008) Commentary: Heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol 37: 1158-1160.